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We have previously noted that when Friend erythroleukemia cells (FLC)' (H-2a)
passaged intraperitoneally in DBA/2 mice were injected subcutaneously or in-
traperitoneally into adult allogeneic immunocompetent mice, they multiplied rap-
idly in the first few days before their further growth was abruptly arrested . In con-
trast, FLC injected intravenously into allogeneic adult C57B1/6 mice, implanted in
the liver and spleen, but did not multiply to any significant degree ; whereas in syn-
geneic DBA/2 mice, they multiplied rapidly and preferentially in these organs and
killed all the mice between 7 and 12 d (1). These observations suggested that when
FLC were injected subcutaneously or intraperitoneally the growing tumors were
rejected after several days in allogeneic mice, whereas when the same cells were in-
jected intravenously and lodged in the liver and spleen they simply could not mul-
tiply in these organs in adult allogeneic mice . It seems plausible that the mecha-
nisms underlying the host response to these tumor cells in these different tissues
are different .
Our previousworkhas suggested that IFN-a/R may constitute an important host
defense against the growth of transplantable tumors : (a) treatment ofathymic nude
mice with anti-mouse IFN-a/p globulin markedly enhanced thesubcutaneous growth
and metastatic capacity ofseveral xenogeneic cell lines (2) ; (b) in adult immunocompe-
tent mice, administration of anti-mouse IFN-a/0 globulin enhanced the growth of
a variety of transplantable murine tumors injected subcutaneously or intraperitoneally
in syngeneic mice but did not abrogate the capacity of allogeneic mice to reject the
growing tumors (3) .
In the studies reported herein, we show that administration of antibodies to IFN-
a/R completely abrogates the resistance of adult C57B1/6 (H-2') andC3H (H-2')
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mice to the rapid multiplication of FLC in the liver. Our results suggest that the
endogenous IFN-a/R induced by intravenous injection of FLC is a crucial compo-
nent in the resistance ofthe liver to the multiplication ofthese allogeneic tumor cells.
Materials and Methods
Mice
Adult DBA/2, C57BI/6, C3H, BALB/c mice were obtained from the pathogen-free breeding
colonies ofthe Institut de Recherches Scientifiques sur le Cancer (Villejuif). Fl hybrid mice
were obtained by mating male or female C57B1/6 with male or female BALB/c. In two ex-
periments, BALB/cBy, C57Bl/6By, and congenic B6.C-H-2d (HW19) mice (4) were a
generous gift of Dr. Edward De Maeyer (Institut Curie, Orsay, France). In all experiments
(unless otherwise specified) adult mice >6 wk old were used.
Mx' -congenic Mice
The congenic B.6A2G-Mx (N20,F4) mouse strain (5) was produced at the Institute for
Immunology and Virology of the University of Zurich by introducing .the influenza virus
resistance allele Mx' of A2G mice (6) into virus-susceptible C57BI/6 mice.
Tumor Cells
The IFN-a/0 resistant clone, 3C18, ofFLC passaged in vitro was obtained from Dr. Affabris,
Istituto Superiore di Sanit3, Rome, Italy (7). These cells were subsequently passaged in our
laboratory by weekly intraperitoneal injection of DBA/2 mice (H-2d) and were highly
metastatic for the liver and spleen (1, 8, 9). In the experiments to be described, tumor cells
were harvested while in the exponential growth phase in the peritoneum.
Quantitative Estimation of the Number of FLC in Liver and Spleen
Colony Formation in Agarose.
￿
The liver or spleen was cut into small pieces with a scalpel
and suspended in 20 ml of a prewarmed (37°C) solution ofcollagenase 100 U/ml (crystalline
collagenase 156 U/mg CLSII; Worthington Biochemical Corp., Freehold, NJ), in RPMI 1640
nutrient medium (Flow Laboratories, Irvine, Scotland) without serum (1). After gentle mixing
on a magnetic stirrer at 37°C for 45 min, the cell suspension was centrifuged, and the cell
pellet was resuspended in 4 ml (liver) or 2 ml (spleen) of RPMI 1640 medium supplemented
with 10% FCS (Flow Laboratories). The total number of FLC recovered was calculated by
the number of FLC colonies in agarose according to techniques previously described (10).
Cells from the liver of normal adult mice do not form colonies in agarose, and only very
few colonies were obtained from the spleen ofnormal mice (<103/spleen) (1). These colonies
could easily be distinguished morphologically from typical FLC colonies in agarose.
Irradiation of FLC
FLC in a petri dish were irradiated with 50 Gy (5,000 rad): (cesium Y rays: 200 rad/min)
by Dr. M. Guichard, H8pital Gustave Roussy, Villejuif, France.
Hyperimmune Anti-IFN Globulins and Normal Serum Globulins
The sources and activities of the different Ig preparations are shown in Table I.
All sera were decomplemented and extensively absorbed on murine cells (11). The Ig frac-
tions were separated by ammonium sulfate precipitation (protein content varied between 20
and 33 mg/ml) and were shown to be devoid of any cytotoxicity (11). The anti-mouse IFN-
a/0 globulins did not neutralize IFN-y.
Sheep Nos. 1 and 5A were immunized with partially purified IFN-a/Q (11), whereas sheep
No. 18-2 was immunized only with highly purified mouse IFN-a/0 (12). Sheep (Mona) poly-
clonal antibody to IFN-a/P(K) (prepared in mouse L cells) serves as the National Institutes
of Health (Bethesda, MD) reference antibody (13). Anti-mouse IFN-0 mAb was produced
and partially purified in our laboratory (F Belardelli) from the hybridoma cell line 7F-D3
(14); a generous gift ofDr. Y. Kawade, Institute for Virus Research, Kyoto, Japan. The R4-6A2GRESSER ET AL.
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TABLE I
Refer-
ence
11
11
-
13
14
15
* IRSC, Institut de Recherches Scientifiques sur le Cancer, Villejuif, France .
t National Institutes of Health, Bethesda, MD. NIH catalog no. G-024-501-568.
rat:mouse hybridomacell line waskindly provided by Dr. E. Haven (Trudeau Institute, Saranac
Lake, NY) (15). The crude tumor ascites was partially purified by Dr. R. Marcowitz in our
laboratory by precipitation with 45% ammonium sulfate. The anti-mouse IFN-y showed
no neutralizing activity at a 1:40 dilution against 8 U of mouse IFN-a/0.
The polyclonal sheep anti-mouse IFN-a/0 globulinswere shown to be completely devoid
of any anti-H-2d, anti-H-2n, or H-2k activity at a 1:2 dilution (these tests were kindly per-
formed by Dr. M. Pla, Laboratory of Mouse Immunogenetics, H6pital Saint-Louis, Paris,
France).
IFNNeutralization Assay
Serial twofold dilutions of Ig were incubated for 1 h at 37'C and 2 h at VC with 4-8
U of mouse IFN-a/0 (C-243 cell IFN) or mouse IFN-y. Mixtures were then incubated with
monolayercultures of Lcells for 18 hbefore challengewith -100 tissue cultureinfective doses
(TCID50) of vesicular stomatitis virus (VSV). In each instance a simultaneous titration of
the IFNused wasincluded in the test. Theneutralizing titerwastaken as the highestdilution
of antibody that inhibited by 50% the protective activity of 4-8 U of IFN. A PHA-induced
spleen cell IFN preparation partially purified on Con A-Sepharose columns was provided
by Dr. E. A. Haven (Trudeau Institute, Saranac Lake, NY).
Anti-Mx Antibody and Immunofluorescence Assayfor the Mx Protein
AP5 is amonospecific anti-Mx antibody produced by immunizing rabbits with asynthetic
peptidecorrespondingto the COOH terminus ofmurine Mx protein(position616-631) (16).
It has the same specificity in immunoprecipitation and immunofluorescence assays as the
Sources andActivities fthe Different Ig Reparations
Description Source
Polyclonal (P) or
monoclonal (M)
IFN
specificity
Neutralizing titer
against 4-8 U of
mouse IFN-a/6 or -y
Anti-mouse IFN
globulins
Sheep No. 1 IRSC* P a/g 6.4 x 106
Sheep No. 5A IRSC P a/0 2.5 x 105
Sheep No. 18-2 IRSC P a/B 4.0 x 104
Sheep (MONA) Research Resources P a/p 5.0 x 104
Branch (NIH)t
Rat:mouse by- Kawade M 6 4.0 x 105
bridoma 7F-D3
Rat:mouse by- Havell (A) M y 6.4 x 104
bridoma R4-6A2 IRSC (B) 1.3 x 105
(C) 1.5 x 105
Control hyperim-
mune globulins
Sheep No. 11 IRSC - - <1 X101
andimpurities
Normal serum
globulins
Sheep No. 2 IRSC - - <1 x 101
Sheep No. 18-1 IRSC - - <1 x 101
preimmunization1274
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polyclonal and monoclonal murine anti-Mx antibodies described previously (17-19) and was
provided by Dr. P. Staeheli (Research Institute of Scripps Clinic, La Jolla, CA).
Frozen 6-8-um cryostat sections of liver and spleen were fixed and permeabilized in 3 %
paraformaldehyde and 0.5% Triton X-100 as described (18) and were then incubated for 15
min with appropriate dilutions of rabbit antibody AP5. Bound antibody was revealed with
rhodamin (TRITC)-conjugated goat anti-rabbit IgG (Cappel Laboratories, Cochranville,
PA). A ReichertJung Polyvar microscope was used for UV incident light fluorescence mi-
croscopy.
Detection of mRNA for Murine Interferons in Organs of Mice
Extraction ofRNAfrom LiverandSpleen.
￿
Quickfrozen liveror spleen was homogenized in
lysis buffer (6 M urea/3 M LiCI/0.1% NaDodS04/heparin 20 U/ml/10 mM sodium acetate,
pH 5.0) and the RNA was precipitated at 0° C, extracted twice with phenol/chloroform, and
chromatographed twice on oligo(dT)-cellulose. Poly(A)' RNA was recovered by precipitating
the RNA with 2.5 vol of ethanol at -20'C overnight and ultracentrifuging the RNA precipi-
tate (100,000 g for 1 h).
RNA Blot Hybridization.
￿
RNA was electrophoresed in 1.5 % agarose gels in the presence
of formaldehyde, transferred to nylon filters (Hybond-N; Amersham Corp., Arlington Heights,
IL) in the presence of 20x SSC (1 x SSC : 0.15 M NaCI/7.5 mM sodium citrate), and irradi-
ated for 4 min at 312 nm (180 W). The RNA blots were prehybridized in 5 x SSC/1 x Den-
hardt's reagent (0.020 /c polyvinylpyrrolidone/0.02% Ficoll/0.02% BSA/100 mM sodium phos-
phate buffer, pH 6.5/0.1% NaDodS04/denatured salmon sperm DNA (100 wg/ml) at 68'C
for 4 h.
RNA was then hybridized to a 600-bp Bam HI-Hinc II fragment of the mouse IFN-a2
gene (20) cloned into the vector pSP64 (21), a cDNA clone of the mouse IFN-0 gene (22),
and a 330-bp Hind III-Cla I fragment containing the first exon of the mouse IFN--t gene
(23) cloned into the vector pBR322 labeled by nick translation to a specific radioactivity of
0.5-4 x 109 cpm/wg of DNA using a-[32P]dATP and a-[32P]dCTP (6,000 Ci/mmol; Amer-
sham Corp.). The blotswere hybridized at 68'C for 20 h in a fresh aliquot of the above solu-
tion. The filters were then washed at 42'C for 2 h in a buffer containing 50% deionized
formamide/5 x SSC/100 mM sodium phosphate and then were repeatedly washed in 0.1 x
SSPE/0.1% NaDodS04 at room temperature. The filters were then exposed to Fuji RX film
with a Cronex intensifying screen (DuPont Co., Wilmington, DE) at -800C .
Results
Role of the MHC in Determining the Multiplication of FLC in the
Liver after Intravenous Inoculation
FLC Injected Intravenously in BALEIc (H-2d) and C57BI16 Mice (H-2b), in FI Hybrid
Mice, and in C57BI16 Mice Congenic with BALBIc Mice at the MHC Locus. FLC pas-
saged in syngeneic DBA/2 mice (H-2d) are highly tumorigenic (10) and when in-
jected intravenously they rapidly multiply in the liver and spleen (1); previous work
has shown that intravenous inoculation of approximately four FLC constitutes 1
LD5o for adult DBA/2 mice (1). FLC also multiplied extensively in the livers of
BALB/c (H-2d) mice but not at all in the livers of adult C57B1/6 (H-2b) mice. We
wanted to determine whether FLC would also multiply in the livers of C57B1/6 mice
congenic with BALB/c mice at the MHC locus. It is clear from the results presented
in Fig. 1 A that fewer FLC were recovered from the livers of congenic mice than
from the livers of BALB/c mice. Likewise, 6 d after intravenous inoculation fewer
FLC were recovered from the livers of Fl C57B1/6 x BALB/c hybrid mice (Fig. 1
B) than from the livers of BALB/c mice. These results indicated that permissivity
for the multiplication of FLC in the liver after intravenous inoculation was not de-
termined solely by the MHC, and that other factors might be involved.Role of Endogenous IFN in Determining Whether FLC Multiply in the Liver of
Allogeneic C57BI16 or C3H Mice after Intravenous Inoculation
FLCMultiply in theLivers ofC57B116Mice Treated with Antibody toMouseIFN-a/O.
￿
Al-
though FLC do not multiply in the livers of adult C57B1/6 mice (Fig. 2, O), they
did multiply rapidlyin thelivers ofall C57B1/6 mice injected with antibody to mouse
IFN-a/D (Figs. 2 and 3, "). FLC do not multiply in the livers of most BALB/c mice
and all BALB/c mice treated with antibody to IFN-a/0 (Fig. 2, A, A). Between the
9th and 12th day after inoculation of tumor cells, two of two other antibody-treated
C57B1/6 mice and five of five other antibody-treated BALB/c mice died with exten-
sive tumorin the liver: whereas three of six BALB/c and zero of two C57BI/6 mice
treated with normal sheep globulin died.
The number oftumor cellsrecovered from theliver 3 h after intravenousinocula-
tion of FLC was the same for mice treated with antibody to IFN-a/R, or control
Ig, or formice left untreated. Thus, injectionofantibody did not affect thehoming
to the liver of FLC injected intravenously (data not shown).
Influence of Various Experimental Conditions Relative to the Multiplication of FLC in
the Livers of C57B116 Mice Treated with Antibody to Mouse IFN-al(3 .
AMOUNT OF ANTIBODY INJECTED.
￿
FLC multiplied in the livers of C57B1/6 mice
pretreated with 2 x 106, 2 x 105, and 2 x 104 neutralizing units of antibody to IFN-
a//3 but not in mice injected with 2 x 103, 2 x 102 neutralizing units (Fig. 4).
NUMBER OF FLC INJECTED.
￿
Although in the experiments described above mice
were injected intravenously with 2 x 106 FLC, it can be seen from Fig. 5 that the
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FIGURE 1. Recovery of FLC from the
livers of BALB/c mice (H-2d),
109 C57B1/6(H-26), C57B1/6 mice (B6-C- 0 0 H-2d) congenic with BALB/c mice at
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0 o the MHC locus and F1 hybrid mice
(C57BI/6 x BALB/c). (A) 12-wk-old
107 male BALB/c (By) mice (A), C57B1/6 a
W (By) mice (O), or C57BI/6mice B6.C-
W H-2d (HW19) congenic with BALB/c
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DAYS AFTER INOCULATION OF FLC
FIGURE 2 .
￿
Multiplication of FLC in the
livers of C57B1/6 and BALB/c mice in-
jected with antibody to mouse IFN-a/(i.
10-wk-old male C57131/6 (0, 0) or
BALB/c (A, A) micewere injected (0.2 ml
i.v.) with 106neutralizing unitsofsheep 1
anti-IFN-a/p globulin (", A) or normal
sheepglobulin (O,A) 2 hbefore an intra-
venous injectionof2 x 106 308 FLC. At
the times indicated, individual mice were
killed andthenumber ofFLC in each liver
was determined by colony formation in
agarose. Each symbol represents the
number of FLC per mouse.
phenomenon of abrogation by anti-IFN globulin ofthe resistance of C57B1/6 to the
multiplication of FLC in theliver wasobserved forall groups regardless ofthenumber
of FLC injected at the dose of antibody injected.
AGE OF MICE.
￿
Although FLC injected intravenouslydo not multiply in the livers
of 6 wk and older C57B1/6 mice, FLC do multiply in the livers of some 4-wk-old
mice (Fig. 6). FLC did multiply in the livers of all 4- and 12-wk-old mice treated
with anti-IFN-a/p globulin (Fig. 6).
TIME OF INJECTION OF ANTI-IFN GLOBULIN.
￿
Injection of anti-IFN-a/0 globulin
3 h before intravenous injection of FLC was more effective in abrogating the resis-
tance of C57B1/6 mice to multiplication of FLC in the liver than injection of the
same amount of globulin 2 or 3 d before tumorcell inoculation (however, this treat-
ment was also effective) (data not shown). The somewhat lowerefficacy of anti-IFN-
a/(3 globulin injected 2-3 d before FLC injection was probably due to the progres-
sive decrease in the circulating serum titerof the anti-IFN globulin in the days after
injection-(11).
RELATIVE NUMBER OF FLC IN LIVER AND SPLEEN.
￿
After intravenous inoculation
of syngeneic DBA/2 mice, FLC multiply extensively and equally in both the liver
and spleen (1). In C57B1/6 mice treated with anti-IFN-a/D globulin, 1,000-fold more
FLC were recoveredfrom theliverthan from the spleen (Fig. 7). Therewas, neverthe-
less, adifference between the number of FLC recoveredfrom the spleen of antibody
treated mice compared with control-treated C57B1/6 mice (Fig. 7).
Effect ofDifferent Anti-IFN Globulin Preparations on theMultiplication ofFLC in the Livers
of C57B1/6 and C3H Mice. In all the above experiments we used potent polyclonal
sheep No. 1 anti-IFN-a/0 globulin to abrogate the allogeneic resistance of C57B1/6
mice (H-2b) to the multiplication of FLC (H-2d) in the liver. The evidence that
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FIGURE 3 .
￿
Foci ofFLC in the liver of aC57B1/6mouse treated with anti-IFN-a/0 globulin. Ex-
perimental conditions were those described in legend to Fig. 2 . C57B1/6 mouse was killed on
day 6 . Note foci of tumor (A) surrounded by normal hepatic parenchyma (B) x 150 . FLC were
not seen in the livers of C57B1/6 mice treated with normal sheep globulin .
abrogation of resistance did not stem from a peculiarity of this particular sheep Ig
may be summarized as follows .
Polyclonal anti-IFN-a/p globulin from another source (Dr . Y Kawade, Institute
for Virus Research, Kyoto, Japan) also abrogated the resistance of C57B1/6 mice
to the multiplication ofFLC in the liver (Fig . 8 A) . Likewise, polyclonal anti-IFN-
a/P globulin from two other sheep immunized in ourlaboratory (one with partially
purified interferon [5A] [11] and the other with highly purified interferon [18-2])
was also equally effective in abrogating resistance in C57B1/6 mice (datanot shown) .
In contrast, normal sheep serum globulins (the preimmunization serum globulins
of sheep No. 18 ; and sheep No. 2, and the serum globulin from sheep No. 11 im-
munized with the impurities in the IFN preparations) did not abrogate the resis-
tance ofC57B1/6 mice, and FLC did not multiply in the livers of these mice (data
not shown) .1278
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FIGURE 4 . Relationship be-
tweenthe amount of anti-IFN-
a/D globulin injected and the
multiplication of FLC in the
livers ofC57BI/6 mice. 8-wk-old
male C57B1/6 mice were in-
jected with various amountsof
sheep 1 anti-IFN-a/p globulin
(0.15ml ix. and0.15ml i.p.) (0)
or left untreated (O) 3 hbefore
"
￿
injection of2 x 106 3C18 FLC.
7 d laterfive mice in each group
were killed and the number of
FLC perliverwasdetermined.
Each symbol represents the
number of FLC/mouse.
6.3 5.3 4.3 3.3 2.3 control
No . OF ANTIBODY UNITS/INJECTION (log1(,)
Administration of monoclonal anti-mouse IFN-R Ig was ineffective in C57B1/6
mice (Fig. 8 A), and monoclonal anti-IFN-y Ig was ineffective in C57111/6 andC3H
mice (Fig. 8, B and C).
Antibody to IFN-a/# also Abrogates the Resistance of C3HMice (H-2k) to theMultiplica-
tion of FLC in the Liver. The experiment illustrated in Fig. 8 (C) shows that poly-
clonal antibody to IFN a/a also abrogates the resistance of C3H mice (H-2') to the
multiplication of FLC in the liver.
Reproducibility oftheEfect ofPolyclonal Antibody to IFN-a/J3 on theMultiplication ofFLC
in the Liver ofAdult C57B1/6Mice. As can be seen in Table II, treatment of adult
C57B1/6 mice with polyclonal antibody to IFN-a/D consistently abrogated the resis-
tance of the liver to multiplication of FLC, whereas FLC did not multiply in the
livers of adult C57B1/6 mice treated with control globulins or left untreated.
Injection ofAnti-Mouse IFN-a/(3 Globulin Results in Death of C57B1/6 and C3HMice
InjectedIntravenously with 3C18 FLC. In sixexperiments some C57B1/6 or C3H mice
treated with anti-IFN-a/p globulins or control globulins were kept for at least 2 mo
to determine the effect of antibody treatment on long-term survival. As can be seen
from Table III, 15 of 18 (83%) C57B1/6 and C3H mice treated with antibody to
IFN-a/a died with massive tumor involvement of the liver 8-13 d after inoculation
of FLC. Syngeneic DBA/2 mice (H-2d) die at this time after intravenous inocula-
tion of FLC (1). In contrast, none of 32 mice treated with control globulins died.FIGURE 5.
￿
Effect of treatment of
C57B1/6 mice with anti-IFN-a/D
globulin on the multiplication of
FLC in theliverafter intravenous
injection of varying numbers of
FLC. 8-wk-old male C57B1/6mice
were injected with 2 x 106 neu-
tralizing unitsofsheep1 anti-IFN-
a/p globulin (0.15 ml i.v. and 0.15
ml i.p.) 3 h before the injection of
varying numbers of 3C18 FLC.
Therewere threeantibody-treated
mice (0) and three control mice
(O) per group. 7dlatermice were
killed and the number of FLC in
theliverwasdetermined by colony
formationin agarose. Each symbol
indicates the number of FLC per
mouse. Twoantibody-treated mice
injected with 107 FLC were dead
on the seventh day. Both hadmas-
sive tumorreplacement oftheliver.
No. OF FLC INJECTED / MOUSE
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Demonstration ofmRNA in the Livers ofC57BI16Mice Injected with 308 FLC Which
Hybridizes with MouseIFN-a and-llDNA Probes. In three experiments usingcell cul-
ture IFN assays, we could demonstrate an antiviral inhibitor (at serum dilutions
of1 :10 to 1:40) in most pools ofserafrom C57B1/6 mice 24 h (but not at 48 h) after
inoculation of 2 x 106 3C18 FLC. As the activity ofthis inhibitor was low it was
difficult to characterize it, so we determined whether injection ofFLC induced the
appearance ofmRNA hybridizable with specific mouse IFN-a or -Q cDNA probes.
In four experiments, poly(A)' RNA harvested from the liver of C57B1/6 mice
8 h after inoculation ofFLC hybridized with the mouse IFN-a2 probe. No hybrid-
ization was detected with RNA from the livers of mice taken 24 h after injection
of FLC or with RNA prepared from uninjected mice (Fig. 9 A). A lower signal of
hybridization was observed with the IFN-a2 probe for poly(A)' RNA extracted
from the spleen 24 h after injection of FLC (data not shown). Newcastle Disease
virus (NDV)-induced IFN-a mRNA in the spleen had an approximate size of 1.2
kb (Fig. 9A). In each experiment the size ofthe hybridizable RNA in the liver(8 h)
or spleen (24 h) after inoculation of FLC was -1.5 kb.
In two experiments, poly(A)' RNA harvested from the liver of mice 8 h after
inoculationofFLC (butnot after24 h norfromuninoculated mice) hybridized with
the mouse IFN-a probe (Fig. 9 B). NDVinduced IFN-R mRNA in the spleen had
an approximate size of 0.9 kb, whereas the RNA in the liver ofFLC-injected mice
had an approximate size of 1.2 kb.
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Recovery ofFLC from
the livers of 4- and 12-wk-old
C57131/6 mice injected with anti-
IFN-a/p globulin. Male C57BI/6
mice were injected with 2 x 106
neutralizing units of sheep I
anti-IFN-a/0 globulin (0.25 ml
i.p.) (0) or left untreated (0) 5 h
before intravenous injection of2 x
101 3C18 FLC. 7 dlatermice were
killed and the number of FLC in
theliverwasdetermined by colony
formationin agarose. Each symbol
indicates thenumber ofFLC/mouse.
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FIGURE 7. Effects of anti-IFN-
a/P globulin on the recovery of
FLC from the liver and spleen of
C57BI/6 mice. 9-wk-old male
C57131/6 mice were injected with 2
x 106 neutralizing units of sheep
1 anti-IFN-a/0 globulin (solid
symbols) or with normal sheep
globulin (opensymbols) (0.15 ml i.v.
and0.1 ml i.p.) 3 hlatermice were
injected intravenouslywith 2 x 106
3C18 FLC. 7 d later mice were
killed and the number of FLC in
0
￿
theliver (0, 0) or spleen (N, 0)
was determined. Each symbol in-
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FIGURE 8.
￿
Effect ofdifferent anti-IFN globulin preparations on themultiplication of308 FLC
in the livers of C57B1/6 and C3H mice (A) 10-wk-old male C57B1/6 mice were injected with
2 x 106 neutralizing unitsof sheep 1 anti-IFN-a/p globulin (0); or 5 x 104neutralizing units
of sheep Mona (K) anti-IFN-a/p globulin (0); or 4 x 105 neutralizing units of anti-IFN-p
globulin (A) or left untreated (O~. Globulins were injected (0.15 ml i.v. 0.1 ml i.p.) 3 h before
intravenous inoculation of 2 x 10 3C18 FLC. 7 days laterthemice were killed and the number
of FLC in the liver of each mouse wasdetermined. In this experiment, FLC multiplied in the
liverof oneuntreatedC57B1/6mouse. This wasthe only instance of 107 untreatedC57B1/6mice
(>6 wk old) in 22 experiments (Table II). (B) 8-wk-old male C57B1/6 mice were injected with
2 x 106 neutralizing units of sheep 1 anti-IFN-a/0 globulin (0); or two different batches of
anti-mouse IFN gamma globulin: 6.4 x 104 neutralizing units (A) or 1.28 x 105 neutralizing
units (B) (")(0.15 ml i.v, 0.1 ml i.p.) or left untreated (O). 3 hlater mice were injected intrave-
nously with 2 x 106 3018 FLC. 7 d later the mice were killed and the number of FLC in the
liverofeach mousewasdetermined. (C)9-wk-old male C3H mice were injected intraperitoneally
with 2 x 106 neutralizing units of sheep 1 anti-IFN-a/0 globulin (0), 1.5 x 105 neutralizing
units ofrat(R4-6A2) anti-IFN-T ("), normal sheep2 serum globulin (A) or were left untreated
(O). Three hours later, mice were injected intravenously with 2 x 106 3C18 FLC. 6 d later the
mice were killed and the number of FLC in the liver of each mouse was determined.
Hybridizable RNA wasnotdetected in extractsofkidney, lung, thymus, ormesen-
teric ganglion usingthe mouse IFN-a2 or-R probes. No hybridizable RNA was de-
tected in organ extracts using a mouse IFN-y probe (data not shown).
Induction ofMxProtein Expression in C57B1/6Mice Congenic withA2GMice at the Mx
Locus. Thepreceding experimentsshowed that afterintravenous injection ofFLC,
mRNA hybridizing with cDNA probes for mouse IFN-a and -a was present in the1282
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TABLE II
Reproducibility of the Effect of Treatment with Polyclonal Antibody to IFN-a/l3
on the Multiplication of FLC in the Liver of Adult C57BI16 Mice
In all these experiments adult C57B1/6 mice (>6 wk old) were injected intravenously with >2
x 106 3C18 FLC. To determine FLC multiplication, the number of FLC in the liver was de-
termined between the fifth and ninth day after intravenous inoculation.
liver at 8 h, and a viral inhibitor was present in very low titer of the serum at 24 h.
As mouse IFN-a/Q (but not IFN-y) induces the expression of the Mx protein in
Mx` mice (24, 25) we determined whether inoculation of FLC into C57B1/6 mice
congenic with A2G mice at the Mx locus would result in the expression of the Mx
protein in the liver and spleen, thus constituting further evidence that injection of
FLC results in the production of IFN-a/(3 .
Accordingly, congenic B6.A2G-Mx mice were injected intravenously with 2 x
106 3C18 FLC and organs were harvested 3, 5, and 7 d thereafter. In uninoculated
Mx' mice there is a background level of Mx protein expressed in a subset of cells
in theliverand spleen (probably in macrophages and endothelial cells) (18, 24) (Fig.
10, A and D), but it is less prominent in otherorgans. In Mx' mice injected intra-
venously with FLC, there was an induction of Mx expression in most hepatocytes
(Fig. 10 E), and cells of the white pulp of the spleen (Fig. 10 B), kidney, and lung
(datanot shown). Administration of anti-IFN-a/0 globulin markedly inhibited this
induced expression of the Mx protein in both the liver and spleen of FLC-injected
mice (Fig. 10, C and F), although it did not appear to affect the low background
level of spontaneous Mx expression (Fig. 10, compare A and D with C and F) .
TABLE III
Mortality in Mice Treated with Anti-IFN-a/p Globulin and Injected Intravenously with FLC
All mice were injected intravenously with 2 x 106 3C18 FLC.
Mice were injected with 2 x 106 neutralizing units of sheep 1 anti-IFN-a/0 globulin.
Control Ig consisted of normal sheep globulin from sheep 11 immunized against impurities in the IFN
preparations.
t All dead mice had extensive gross tumor invasion of the liver.
Mouse strain
Number of
experiments Treatment'
Number of mice deadl/
total number
Mean day of
death t SE
C57B1/6 6 Anti-IFN a/p 13/15 9.7 t 0.3
Control Ig 0/25 -
C3H 1 Anti-IFN a/p 2/3 11 .5 t 1 .5
Control Ig 0/7 -
Treatment
Number of
experiments
Number of mice in which
FLC multiplied in the liver/
total number of mice injected Percentage
None 22 1/107 1
Control globulins 7 0/36 -
Polyclonal antibody
to IFN a/0 23 100/102 98GRESSER ET AL .
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FIGURE 9.
￿
Northern blot hybrid-
ization analysis of IFN-a and -p
mRNA in the livers of 8-wk-old
male C57B1/6 mice injected intra-
venously with 3C18 FLC. (A) Hy-
bridization with cloned murine
IFN-a2 DNA; (B) hybridization
with cloned murine IFN-0 cDNA .
The film was exposed for 4 d at
-80°C . Lanes 1 and 2 are the
poly(A)* RNAfrom the spleens of
C57B1/6 mice injected intrave-
nouslywith Newcastle disease virus
as a positive control for the induc-
tion of mRNA for IFN-a and -R .
A: 0.5 and 0.2 pg/B : 1 .0 and 0.5
pg) . Lane 3, RNAfrom liver from
uninjected C57B1/6 mice; lanes 4
and5 ; RNAfrom livers ofC57B1/6
mice killed 8h (lane 4)or 24 h (lane
5) after intravenous injection of
FLC . 20 pg of poly(A)' RNA
were loaded per sample in lanes
3-5 .
Serial Passage ofFLC in C57B1/6Mice Treatedwith Anti-IFN-a/p Globulin Does Not
Result in the Emergence ofFLC Capable ofMultiplying in Untreated C57B1/6 Mice
The preceding results indicated that after intravenous inoculation, FLC multi-
plied in the livers of C57B1/6 or C3H mice treated with antibody to mouse IFN-
a/(3 . It might be hypothesized that injection of FLC from syngeneic DBA/2 mice
into these anti-IFN globulin-treated allogeneic mice resulted in the selection of a
population oftumor cells (perhaps with an altered H-2 expression) capable of mul-
tiplying in untreated C57B1/6 mice. Likewise, it might be hypothesized that injec-
tion ofFLC liberated a factor (virus ?) that induced a transformation of host cells
inC57B1/6 mice treated with anti-IFN-a/R globulin . We undertooktwo experiments
to test these hypotheses .
First, FLC were serially passaged every 7 d for 10 passages in C57B1/6 mice treated
with 106 neutralizing units of anti-mouse IFN-a/0 globulin . At each passage, 2 x
106 FLC from the livers of antibody treated mice were injected intravenously into
three other antibody-treated or three untreated mice. At each passage level, FLC
multiplied only in the livers of mice pretreated with antibody to IFN-a/0 and never
in the livers of untreated mice . After the second and tenth passage of FLC in the
livers of antibody-treated mice, theseFLC were injected both intravenously and sub-
cutaneously into untreated allogeneic C57B1/6 mice and also into syngeneic DBA/2
mice.FLC formed large subcutaneous tumors and multiplied extensively in the livers
ofDBA/2 mice (compared in the same experiment withFLCpassaged intraperitoneally
in DBA/2 mice) but did not multiply in untreatedC57B1/6 mice . These results indi-
cated that passage ofFLC in the livers of antibody-treated C57B1/6 mice was not
associated with acquisition of the capacity to multiply in the livers (or subcutane-1284
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FIGURE 10 .
￿
Induction ofMx protein expression in Mx' C57B1/6 mice injected intravenously
with 308 FLC. 5-mo-old male congenic B6.A2G-Mx' mice were separated into three groups.
One group was not injected (A, D) ; one group was injected (0 .2 ml i.p .) with normal sheep 2
serum globulin (B, E) ; one group was injected with 2 x 10 6 i.p. neutralizing units of sheep 1
anti-IFN-a/p globulin C, F). 3 h later mice in groups B, C, E, andFwere injected intravenously
with 2 x 10 6 3C18 FLC. 3 d later frozen cryostat sections of spleen (A, B, C) and liver (D, E,
F) were stained by indirect immunofluorescence with specific anti-Mx antibodies. Note thatMx'
cells are present in a subset ofcells ofspleen and liver of uninjectedMx' mice (A, D) (24) . Note
marked increase in expression ofMx protein in cells (nuclei [18, 25]) ofspleen and liveroftumor-
injected, control serum-treated Mx' mice (B, E) . Note relative decrease in expression ofMx
protein in spleen and liver of tumor-injected Mx' mice preinjected with antibody to IFN-a/0
(C, F) compared with B, E.
ously) of untreated allogeneic C57B1/6 mice or in a decreased tumorigenicity for
syngeneic DBA/2 mice.
In a second experiment, FLC were irradiated with 5,000 rad, which abolished
their capacity to multiply in the liver of C57B1/6 mice treated with anti-IFN-a/P
globulin (or left untreated) . These resultsindicatedthat theinjected FLC must haveGRESSER ET AL.
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the capacity to multiply in order to induce tumors in the livers of C57B1/6 mice
treated with antibody to IFN-a/(3 . These results do not support, therefore, the hy-
pothesis that virus released from FLC induced a transformation of host cells.
Discussion
The results presented herein suggest the possibility that the mechanisms opera-
tive in restricting transplantable tumor growth in allogeneic mice may be different
depending on the site of tumor growth. For example, transplantable mouse tumors
usually grow for several days when injected subcutaneously or intraperitoneally into
allogeneic mice before rejection. Thus, in previous experiments FLC (H-2d) in-
jected intraperitoneally into allogeneic C57B1/6, C3H, or Swiss mice multiplied 500-
fold in the peritoneum by the fifth day (comparable numbers of FLC were present
in the peritoneum of syngeneic mice at this time) before being eliminated in the
ensuing fewdays (our unpublished observations). It is usuallyaccepted that immune
mechanisms are responsible for this tumor cell rejection across a strong MHC bar-
rier (26).
In contrast, when FLC were injected intravenously they implanted in the liver
of syngeneic DBA/2 and allogeneic C57B1/6 mice to the same extent (see Fig. 2;
3 h after injection), but multiplied only in the livers of syngeneic mice and not to
any significant degree in the livers of adult allogeneic mice. We are not aware of
a distinction having been made, heretofore, between rejection of a growing tumor
and failure of the tumor to grow at all in the adult allogeneic host. Furthermore,
the behavior of tumorcells injected intravenously into hybrid or congenic mice sug-
gested that factors in addition to the MHC may be important in restricting tumor
growth in different organs after intravenous inoculation. Thus, several days after
intravenous inoculation, 100-fold fewer FLC could be recovered from the livers of
C57B1/6 mice congenic with BALB/c mice at the MHC locus (or from F1 hybrid
C57B1/6 x BALB/c mice) than from the livers of BALB/c mice (H-2d) (Fig. 1). Like-
wise, after intravenous inoculation of the B16 melanoma, -10-fold fewer tumor
nodules were observed in the lungs of F1 hybrid mice compared with the lungs of
syngeneic mice (27). In contrast, no difference was observed in mesenteric tumor
formation between syngeneic and F1 hybrid mice when the tumorcellswere injected
intraperitoneally (27). Jack and McVeigh concluded that after intravenous injection,
tumor growth in the lung was restricted by a "locus other than H-2" (27).
The results presented herein strongly suggest that IFN-a/0 is one of the impor-
tant factors in restricting FLC multiplication in the liver after intravenous inocula-
tion of allogeneic mice. Whereas administration of antibody to IFN-a/a did not pre-
vent tumor cell rejection when tumor cells were injected subcutaneously or
intraperitoneally into allogeneic mice (3), this antibody completely overcame the
barrier to FLC multiplication in the livers of adult allogeneic immunocompetent
mice. Thus, in antibody-treated C57B1/6 or C3H mice, FLC injected intravenously
multiplied rapidly in theliver(asdetermined by quantitative estimations of the number
of FLC [Figs. 2, 4-8] and histopathologic examination [Fig. 3]) and almost all the
mice died with extensive tumorinvasion ofthe liver (Table III). In fact, the kinetics
of FLC muliplication in the liver of C57B1/6 mice treated with anti-IFN-a/R globulin
(Fig. 2) and the mean day of death of these mice resembled that observed in syn-
geneic DBA/2 mice. The effect ofantibody treatmentof allogeneic mice in abrogating1286
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liver resistance was highly reproducible (Table II) under a variety of experimental
conditions (i.e., varying numbersof FLC injected, age ofmice, amount ofantibody)
as detailed in Figs. 4-6.
Several arguments attest to the specificity of the antibodies to IFN-a/R used: (a)
Polyclonal antibodies raised in threesheep in our laboratory against either partially
purified C243 cell IFN-a/(3 (sheep 1-8, and 5A), or highly purified mouse IFN-a/0
(12) (sheep 18), or antibody from a sheep (Mona) prepared in another laboratory
against mouse Lcell IFN all proved effective in abrogating the resistance ofC57B1/6
or C3H mice to the multiplication of FLC in the liver (Table I, Fig. 8). (b) Neither
antibody raised in sheep 11 against the impurities in the IFN-a/(3 preparations or
the serum globulin from two normal sheep (one being the preimmunization serum
of sheep 18) exerted any effect .
These considerations suggest that these anti-IFN-a/R globulins acted by neu-
tralizingeither "spontaneous" endogenous IFN-a/R present before injection oftumor
cells or an endogenous IFN-a/0 resulting from the intravenous injection of FLC.
Although we have not detected IFN in normal mice, otherinvestigators have demon-
stratedthe presence of small amounts ofIFN-a/0 in the serum ofa few normal mice
(28) and our previous work using antibody to IFN-a/0 has provided indirect evi-
dence to suggest the presence of biologically active "spontaneous" endogenous IFN
in mice (29-31). More recently we have shown that the mRNA for IFN-al and -a2
is present in various tissues of normal individuals in the apparent absence of an in-
ducer (32).
To our knowledge there have been very few previous reports demonstrating the
production of interferon in experimental animals after inoculation of tumor cells
(33, 34), although tumor cells have been shown to induce interferon production by
lymphocytes in vitro (35, 36). Several experimental results strongly indicated that
in our experiments the intravenous inoculation of FLC does result in the induction
of IFN: (a) 8 h after intravenous inoculation of FLC, poly(A)+ RNA hybridizable
with specific DNA probes formouse IFN-a2 and -R was detectable in the liver (Fig.
9) (hybridizable poly(A)' RNA was also present in the spleen at 24 h).2 (b) Using
IFN cell culture assays a viral inhibitor of low activity was detected in the serum
of C57B1/6 mice 24 h after injection of 308 FLC. (c) To date only IFN-a/0 has
been shown to induce the expression of Mx protein in Mx' cells (24). Injection of
C57B1/6 mice with FLC resulted in the induced expression of the Mx protein in
most cells of the liver, spleen (Fig. 10, B and E), lung, and kidney, and this enhance-
ment was blocked by treatment of the mice with anti-IFN-a/0 globulin (Fig. 10, C
and F). The most likely explanation of our results appears to be that intravenous
injection of 3C18 FLC results in the induction of IFN-a/0 that was neutralized by
potent polyclonal antibody to IFN-a/0.
We do not mean to imply, however, that IFN is the sole factor in determining
the resistance of the liver to allogeneic tumor growth, but it does seem to be one
of the important factors. IFN may also play a role in the resistance of the liver of
syngeneic mice to FLC injected intravenously, but the effect is less obvious as the
2 If both IFN-a and -p mRNAsaretranslated, this may explain the failure ofamonoclonal anti-IFN-
p globulin alone to abrogate resistance of C57B1/6 mice (Fig. 8). Unfortunately apotent monoclonal
anti-IFN-a globulin was not available to permit us to test the combined effect of both mAbs.GRESSER ET AL.
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tumor cells multiply so rapidly. FLC injected intravenously into BALB/c mice
(H-2d) congenic with A2G mice at the Mx locus also induced an increase in the
expression of the Mx protein in the liver, spleen, lung, and kidney, therefore indi-
cating the production of IFN-a/R (data not shown). Injection of syngeneic DBA/2
mice (H-2d) with antibody to IFN-a/0 decreased the mean day of death from
9.0 ± 0.6 d for control FLC-injected mice to 7.0 ± 0 days for antibody-treated
mice (p < 0.01) (data not shown). Lastly, FLC do multiply in the livers of allogeneic
nu/nu mice (data not shown).
Landolfo and colleagues (37) showed that monoclonal antibodies to mouse IFN-y
abrogated alloantigen recognition and induction of CTL in mixed leukocyte reac-
tions. When allogeneic mice were injected with a fibrosarcoma, and treated repeat-
edly with an mAb to mouse IFN-y, tumor rejection did not occur. In our experi-
ments, intravenous inoculation of FLC did not result in the appearance in any of
the tissues tested of a poly(A)+ RNA hybridizable with a mouse IFN-y cDNA
probe. Likewise, treatment of allogeneic C57B1/6 or C3H mice with a potent mAb
to mouse IFN-y did not abrogate the resistance to multiplication ofFLC in the liver
(Fig. 8). Thus, in our experiments we found no evidence that IFN-y played an im-
portant role, emphasizing once more the possibility that the site of tumor growth
may elicit different host mechanisms and different inhibitory factors.
In our previous work (1) on the antitumor effects of IFN we have shown that ad-
ministration of IFN markedly inhibits the multiplication ofIFN-resistant 3C18 FLC
in the liver and spleen of syngeneic DBA/2 mice, even after these cells were present
in large numbers in these target organs. As we could show that these 3C18 FLC
were resistant to several activities of IFN in vivo (as well in vitro) (38, 39), we postu-
lated that the antitumor effect of IFN was not due to a direct effect of IFN on the
tumor cells themselves, but was host mediated (1). The nature of the host mecha-
nisms remains obscure, but we have found no evidence that humoral or cellular im-
mune mechanisms played an importantrole (40). Likewise, in theexperimentsreported
herein we have used the IFN-resistant 3C18 line of FLC. As we still have no clear
idea how exogenous IFN acts in syngeneic tumor-injected mice, it is premature to
speculate how endogenous IFN might act in restricting FLC muliplication in the
liver of allogeneic mice. In allogeneic mice treated with antibody to IFN-a/a, FLC
multiplied to a far greater extent in the liver than in the spleen (Fig. 7), whereas
in syngeneic mice these FLC multiplied equally well in the liver and spleen. These
results suggest that multiple factors are operative in determining the organ resis-
tanceto tumor cell multiplication and that IFN may be more important in the liver
than in the spleen.
To our knowledge it is not known whether autochtonous primary or metastatic
tumors in man elicit an IFN response. As tumormetastases in theliverdo notalways
grow rapidly andexponentially, it seemsreasonable to suggest that the rate of tumor
growth in certain tissuesmaybe determined not only by the inherent growth pattern
of the individual tumor but also by the presence of soluble growth inhibitors such
as IFN.
Likewise, it is unknown whether transplantation of normal liver induces an IFN
response in the immunodepressed host, although it has been shown that IFN-a/0
is induced in mice in the course of graft-vs.-host disease (41). The finding that in
experimental animals "foreign liver is often better tolerated than otherorgan grafts1288
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(skin, kidney, or heart) being rejected less aggressively or requiring less immunosup-
pression to prevent rejection" (42) may suggestthat mechanisms responsible forliver
rejection are qualitatively or quantitatively different from those observed in other
grafts. In a recent review on the immunology of liver transplantation in the rat,
Kamada summarized as follows: "It seems quite likely that rejection of liver grafts
across a whole haplotype barrier is under multigenic control, with important roles
both forclassical MHC-linked Ir genes andfornon-MHC-linked background genes"
(42). If IFN production is important in liver transplantation it would be of interest
to determine whether administration of antibody to IFN would facilitate liver (or
other organ) transplantation in experimental animals (and possibly in man).
Summary
Friend erythroleukemia cells (FLC) (H-2d) injected intravenously into adult syn-
geneic DBA/2 or allogeneic C57B1/6 (H-2b) or C3H (H-2k) mice lodge in the liver
but only multiply in the liver of syngeneic mice. Our results indicated that endoge-
nous IFN-a/(3 was a crucial factor in preventing the multiplication of FLC in the
liver of adult allogeneic mice. (a) Treatment of allogeneic adult C57BI/6 or C3H
mice with polyclonal antibody to mouse IFN-a/0 (but not antibody to IFN-y) com-
pletely abrogated the resistance to the multiplication of FLC in the liver and 87%
oftumor-injected, antibody-treated C57B1/6 mice died with extensivetumorinvolve-
ment of the liver. In contrast, after intravenous inoculation FLC do not multiply
at all (or very rarely) in the liver of adult C57B1/6 mice left untreated or treated
with a variety ofcontrol globulins, andno deaths occurred. (b) 8 h afterintravenous
inoculation of FLC, poly(A)+ RNA hybridizable with specific DNA probes for
mouse IFN-a or -R (but not -y) was present in the liver of injected C57BI/6 mice.
Using the expression of the Mx protein as an indicator of the presence of IFN-a/R,
we showed that Mx' congenic C57B1/6 mice injected with FLC exhibited a marked
increase in the expression of the Mx protein in the liver, spleen, kidney and lung,
and this increase was blocked by treatment of mice with antibody to IFN-a/0. The
possibility that different host mechanisms are elicited depending on the site oftumor
growth in allogeneic mice is discussed. IFN-a/R appears to be of particular impor-
tance in determining the resistance of the liver to FLC in allogeneic mice.
We are grateful to ProfessorsJean Lindenmann andRolfZinkernagel andDr. Michel Aguet
(Zurich) for helpful discussions.
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